




RealRate

# PHARMACEUTICAL 2018

## GYRE THERAPEUTICS INC. Rank 145 of 342





# PHARMACEUTICAL 2018

## GYRE THERAPEUTICS INC. Rank 145 of 342



The relative strengths and weaknesses of GYRE THERAPEUTICS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of GYRE THERAPEUTICS INC. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 111% points. The greatest weakness of GYRE THERAPEUTICS INC. is the variable Net Income, reducing the Economic Capital Ratio by 23% points.

The company's Economic Capital Ratio, given in the ranking table, is 130%, being 84% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	39,109
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	8,739
Liabilities, Non-Current	0
Other Assets	128
Other Compr. Net Income	1.0
Other Expenses	0
Other Liabilities	0
Other Net Income	1,279
Other Revenues	0
Property and Equipment	276
Research and Development	12,847
Selling, General and Administrative Expense	9,993

Output Variable	Value in 1000 USD
Assets	39,513
Liabilities	8,739
Expenses	22,840
Revenues	0
Stockholders Equity	30,774
Net Income	-21,561
Comprehensive Net Income	-21,560
Economic Capital Ratio	130%